Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 12/20 | 0.58 |
| ▸ | RPTOR | Q8N122 | 6/20 | 0.58 |
| ▸ | MLST8 | Q9BVC4 | 6/20 | 0.58 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.33 |
| ▸ | CDK2 | P24941 | 5/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14298607 | 1.00 | MTOR (0.58) | MTORRPTORMLST8MAP3K12BRAF | |
| SCHEMBL14245833 | 1.00 | MTOR (0.58) | MTORRPTORMLST8MAP3K12BRAF | |
| SCHEMBL14245959 | 0.95 | MTOR (0.57) | MTORRPTORMLST8MAP3K12BRAF | |
| SCHEMBL14298618 | 0.95 | MTOR (0.57) | MTORRPTORMLST8MAP3K12BRAF | |
| SCHEMBL14246564 | 0.95 | MTOR (0.57) | MTORRPTORMLST8MAP3K12BRAF | |
| SCHEMBL2147904 | 0.95 | MTOR (0.57) | MTORRPTORMLST8MAP3K12BRAF | |
| SCHEMBL14246562 | 0.95 | MTOR (0.57) | MTORRPTORMLST8MAP3K12BRAF | |
| SCHEMBL14246563 | 0.95 | MTOR (0.57) | MTORRPTORMLST8MAP3K12BRAF | |
| SCHEMBL17399321 | 0.93 | MTOR (0.56) | MTORRPTORMLST8BRAFCHEK1 | |
| SCHEMBL2170325 | 0.93 | MTOR (0.56) | MTORRPTORMLST8BRAFCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | claimed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | claimed |
| WO-2011090935-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | claimed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| WO-2011090935-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPS6KA5 | MTOR 1/4885RPTOR 4/4885MLST8 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.